menu
    • menu
    [{"orgOrder":0,"company":"Kinea Bio","sponsor":"Solid Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Licensing Agreement","leadProduct":"KNA-155","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kinea Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinea Bio \/ Kinea Bio","highestDevelopmentStatusID":"4","companyTruncated":"Kinea Bio \/ Kinea Bio"},{"orgOrder":0,"company":"Kinea Bio","sponsor":"Jain Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Funding","leadProduct":"KNA-155","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kinea Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinea Bio \/ Jain Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Kinea Bio \/ Jain Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by Kinea Bio

    Menu

    Kinea Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kinea Bio

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Kinea Bio

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KNA-155

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : Solid Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Solid Biosciences Inks Licensing Deal with Kinea Bio for Next-Gen Capsid AAV-SLB101 Use

                            Details : Kinea Bio will use Solid’s next-generation capsid, AAV-SLB101, for the development of KNA-155, an investigational dual AAV gene therapy.

                            Product Name : KNA-155

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 23, 2025

                            Lead Product(s) : KNA-155

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : Solid Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kinea Bio

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Kinea Bio

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KNA-155

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Jain Foundation

                            Deal Size : $1.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Kinea Bio Secures $1.1M Investment to Advance Gene Therapy for Dysferlinopathy

                            Details : The funding will support the KNA-155, including dose-finding and GLP toxicology studies in dysferlin-deficient animal models.

                            Product Name : KNA-155

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 23, 2025

                            Lead Product(s) : KNA-155

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Jain Foundation

                            Deal Size : $1.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth